Alkeon Capital Management
KROS icon

Alkeon Capital Management’s Keros Therapeutics KROS Stock Holding History

Alkeon Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-850,511
Closed -$13.5M – 118
2025
Q3 		$13.5M Hold
850,511
– – 0.02% 101
2025
Q2 		$11.4M Hold
850,511
– – 0.02% 94
2025
Q1 		$8.67M Sell
850,511
-250,489
-23% -$2.91M 0.02% 96
2024
Q4 		$17.4M Sell
1,101,000
-796,601
-42% -$41.4M 0.04% 83
2024
Q3 		$110M Buy
1,897,601
+298,694
+19% +$14.8M 0.19% 58
2024
Q2 		$73.1M Hold
1,598,907
– – 0.12% 73
2024
Q1 		$106M Buy
1,598,907
+100,000
+7% +$5.93M 0.18% 63
2023
Q4 		$59.6M Sell
1,498,907
-177,615
-11% -$5.57M 0.13% 70
2023
Q3 		$53.4M Hold
1,676,522
– – 0.1% 78
2023
Q2 		$67.4M Sell
1,676,522
-1,496
-0.1% -$65.6K 0.12% 75
2023
Q1 		$71.7M Buy
1,678,018
+285,616
+21% +$14.4M 0.16% 77
2022
Q4 		$66.9M Buy
1,392,402
+183,580
+15% +$8.58M 0.26% 77
2022
Q3 		$45.5M Buy
1,208,822
+32,389
+3% +$1.12M 0.15% 96
2022
Q2 		$32.5M Buy
1,176,433
+270,000
+30% +$11.8M 0.09% 107
2022
Q1 		$49.3M Sell
906,433
-20,000
-2% -$1.03M 0.1% 113
2021
Q4 		$54.2M Buy
926,433
+225,000
+32% +$11.2M 0.1% 105
2021
Q3 		$27.7M Sell
701,433
-2,006
-0.3% -$71.4K 0.05% 127
2021
Q2 		$29.9M Buy
703,439
+180,000
+34% +$9.75M 0.04% 127
2021
Q1 		$32.2M Buy
523,439
+1,318
+0.3% +$83.5K 0.05% 124
2020
Q4 		$36.8M Buy
522,121
+492,121
+1,640% +$31M 0.06% 125
2020
Q3 		$1.16M Hold
30,000
– – ﹤0.01% 143
2020
Q2 		$1.13M Buy
+30,000
New +$924K ﹤0.01% 143

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Alkeon Capital Management's KROS Position: Q4 2025 in Review

Alkeon Capital Management sold out of Keros Therapeutics (KROS) in Q4 2025, closing a stake of 850,511 shares — an estimated $13.5M sold.

Alkeon Capital Management first reported a position in KROS in Q2 2020 and held it in 22 quarters. The position peaked at $110M in Q3 2024. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

  • Alkeon Capital Management reported no remaining Keros Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Alkeon Capital Management sold 850,511 Keros Therapeutics shares in Q4 2025, an estimated $13.5M.
  • Alkeon Capital Management first reported a position in Keros Therapeutics in Q2 2020 and held it in 22 quarters.
  • Alkeon Capital Management's Keros Therapeutics position peaked at $110M in Q3 2024.
  • 166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on Alkeon Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.